Marketing Surveillance and Pharmacovigilance: QA’s Role in Ensuring Product Safety

Abstract

Post-marketing safety of pharmaceutical products is a critical aspect of public health, requiring the integration of marketing surveillance, pharmacovigilance, and quality assurance (QA). Marketing surveillance ensures that medicines in the market meet established quality standards, comply with regulatory requirements, and remain free from defects throughout distribution. Pharmacovigilance complements this by continuously monitoring, detecting, assessing, and preventing adverse drug reactions, thereby maintaining a favorable benefit–risk profile over the product’s lifecycle. QA serves as the backbone of these processes, enforcing standard operating procedures, conducting audits, maintaining data integrity, and implementing corrective and preventive actions to uphold product safety. Historical incidents, such as the thalidomide tragedy, highlight the consequences of inadequate oversight, reinforcing the importance of robust QA systems. With the advent of advanced data analytics, artificial intelligence, and global regulatory collaboration, modern pharmaceutical safety monitoring has become more proactive and efficient. However, challenges such as fragmented reporting systems, regulatory complexity, and resource limitations remain. A well-coordinated, quality-driven approach that harmonizes marketing surveillance and pharmacovigilance ensures that pharmaceutical products are consistently safe, effective, and reliable for patients worldwide.

Keywords

Marketing Surveillance, Pharmacovigilance, Quality Assurance, Post-marketing Safety, Adverse Drug Reactions

Introduction

Table 1: Key Activities in Marketing Surveillance and Pharmacovigilance

2.5 Global examples

2.5.1 India

The Central Drugs Standard Control Organization (CDSCO), which collaborates with state drug control authorities, keeps an eye on the market, paying particular attention to shoddy and counterfeit drugs. Reports from field inspectors and laboratory testing are regularly compiled to guide regulatory actions, including product recalls and alerts ⁵.

2.5.2 United states

The FDA's Drug Quality Reporting System (DQRS) gathers reports of drug quality flaws and helps manufacturers and the FDA coordinate quickly to resolve problems.

2.5.3 Africa

Programs such as the Promoting the Quality of Medicines (PQM) initiative of the United States Pharmacopeia (USP) help to improve market surveillance capabilities in order to detect inferior medications that could lead to antibiotic resistance and treatment failure.

2.6 Importance for Public Health

Effective marketing surveillance lowers healthcare costs associated with treatment failures or adverse events, safeguards patients from dangerous or ineffective medications, and upholds confidence in pharmaceutical supply chains ⁶. Additionally, it helps regulatory bodies protect vulnerable groups and enforce standards.

3. Pharmacovigilance

3.1 Definition and Scope

The World Health Organization (WHO) defines pharmacovigilance as "the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems." In the broader context of drug safety, it also addresses prescription errors, drug interactions, and lack of efficacy in addition to tracking adverse drug reactions (ADRs) ⁷. Pharmacovigilance is essential for drugs to have a favourable benefit-risk balance both after they are approved and for the rest of their commercial lives. It primarily relies on systematic data collection and analysis to evaluate known threats in the general population and identify unidentified risks.

3.2 Objectives

The main objectives of pharmacovigilance include:

• Detecting new or rare adverse drug reactions.
• Evaluating the frequency and severity of known ADRs.
• Understanding risk factors and patient populations at higher risk.
• Preventing harm by recommending regulatory actions, label changes, or product withdrawals.
• Promoting safe, rational, and effective use of medicines.

3.3 Pharmacovigilance systems and methods

3.3.1 Spontaneous reporting systems (SRS)

Globally, voluntary or impromptu reporting by patients and healthcare professionals is crucial to pharmacovigilance. National databases like the FDA's MedWatch (USA), EudraVigilance (Europe), and the Pharmacovigilance Programme of India (PvPI) collect millions of Individual Case Safety Reports (ICSRs) annually ⁸.

Advantages:

• Cost-effective.
• Useful for detecting rare ADRs.

Limitations:

• Underreporting estimated at over 90%.
• Reporting bias and incomplete data.

3.3.2 Cohort event monitoring (CEM)

CEM involves the prospective monitoring of a particular group of patients taking a particular medication over time in order to identify all health occurrences. This active surveillance approach provides incident rates and a more thorough understanding of medication safety.

Challenges:

• Resource intensive.
• Requires robust infrastructure.

3.3.3 Case–control and Cohort studies

By contrasting patients with and without unfavourable outcomes, these observational epidemiological studies assess risk factors and causality. They provide more compelling evidence than impromptu reports, but they are also more complicated and expensive.

3.3.4 Data mining and signal detection

Large datasets are analysed by sophisticated statistical algorithms to find ADRs that are reported disproportionately, which could indicate possible safety concerns ⁹. Artificial intelligence and machine learning are increasingly being used together to increase the effectiveness of signal detection.

3.4 Pharmacovigilance processes

Process Step	Description
Case Collection	Gathering individual case safety reports (ICSRs) from various sources including healthcare professionals, patients, literature, and clinical trials.
Case Assessment	Evaluation of reports for completeness, causality, seriousness, and expectedness of ADRs.
Signal Detection	Identification of new safety signals through data analysis and clinical review.
Risk Evaluation	Assessing the benefit-risk profile of the medicine considering all data.
Regulatory Reporting	Submission of Periodic Safety Update Reports (PSURs), Risk Management Plans (RMPs), and other safety documents to regulatory authorities.
Communication	Informing healthcare professionals, patients, and stakeholders about new safety information and recommendations.

3.5 Examples of pharmacovigilance impact

3.5.1 Withdrawal of rofecoxib

Post-marketing surveillance identified increased cardiovascular risks associated with the COX-2 inhibitor rofecoxib, leading to its global withdrawal in 2004.

3.5.2 Detection of stevens-johnson syndrome with lamotrigine

Pharmacovigilance data revealed rare but severe cutaneous reactions to the antiepileptic lamotrigine, prompting updated prescribing guidelines and boxed warnings.

4. Regulatory Framework

4.1 International regulatory guidelines and programs

Vigi Base, the largest global database of Individual Case Safety Reports (ICSRs), is maintained by the WHO PIDM, which was established in 1968 and coordinates international efforts to monitor drug safety ¹⁰. The impromptu reports from member countries help with international risk assessment and signal detection. The program encourages regulatory advice, training, and capacity building in participating countries.

4.1.1 World health organization (WHO) programme for international drug monitoring (PIDM)

The WHO PIDM, which was founded in 1968, oversees VigiBase, the largest global database of Individual Case Safety Reports (ICSRs), and coordinates global efforts to monitor drug safety. International risk assessment and signal detection are aided by the spontaneous reports from member nations. In participating nations, the program promotes capacity building, training, and regulatory guidance.

4.1.2 International council for harmonisation of technical requirements for pharmaceuticals for human use (ICH)

E2E Pharmacovigilance Planning, one of the comprehensive guidelines created by the ICH, outlines the specifications for risk management plans, pharmacovigilance system management, and periodic safety update reports ¹¹. These regulations, which promote consistency in drug safety standards, have been widely accepted by regulatory agencies in the US, Europe, Japan, and other nations.

4.2 Regional regulatory systems

4.2.1 United states food and drug administration (FDA)

The FDA oversees pharmacovigilance through the MedWatch program, which collects voluntary reports of adverse events and medication errors from patients and medical professionals. The FDA also requires manufacturers of high-risk drugs to submit Periodic Safety Update Reports (PSURs) and employ Risk Evaluation and Mitigation Strategies (REMS)¹². The FDA actively monitors drug safety signals and can respond with safety communications, label changes, or product recalls.

4.2.2 European medicines agency (EMA)

The EMA manages pharmacovigilance across the EU through the EudraVigilance system, which collects and analyses ICSRs from member states. The European Medicines Agency (EMA) enforces the Good Pharmacovigilance Practices (GVP) standards, which outline precise requirements for risk management, signal detection, and pharmacovigilance system audits. The agency collaborates with national competent authorities to ensure consistent execution.

4.2.3 Pharmacovigilance programme of india (PvPI)

The Indian Pharmacopoeia Commission (IPC), which oversees PvPI, was established in 2010 with the goal of enhancing drug safety oversight in India. It operates a nationwide network of Adverse Drug Reaction Monitoring Centres (AMCs) to collect spontaneous reports and supports capacity building through training and awareness campaigns. PvPI gives the WHO PIDM safety data and takes part in national regulatory decisions.

4.3 Regulatory requirements for marketing surveillance

Regulatory agencies mandate that businesses conduct marketing surveillance in order to comply with Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP) ¹³. Regular quality assessments and post-marketing product quality surveillance are necessary for regulatory inspections and product license renewals. Manufacturers must report any significant quality defects or deviations that could jeopardize patient safety, and regulators have the authority to order product recalls or market withdrawals as necessary.

5. Quality Assurance In Marketing Surveillance and Pharmacovigilance

5.1 QA activities in marketing surveillance

The purpose of the systematic quality assurance (QA) process is to ensure that all pharmacovigilance and marketing surveillance-related activities comply with regulatory requirements, business policies, and industry best practices. Ultimately, QA is essential to maintaining the accuracy, reliability, and integrity of the data generated by these systems, promoting patient safety and legal compliance. Quality assurance (QA) in pharmacovigilance and marketing monitoring includes the development and application of Standard Operating Procedures (SOPs), audits, documentation management, employee training, and the oversight of corrective and preventative measures (CAPA).

5.1.1 SOP development and compliance

QA teams develop standard operating procedures (SOPs) that govern how marketing surveillance activities, including sample techniques, complaint handling, and distribution monitoring, are carried out. These SOPs must adhere to legal requirements as well as Current Good Manufacturing Practices (cGMP). Regular reviews ensure that SOPs remain up to date with evolving requirements.

5.2 Audits and inspections

QA carries out internal audits to guarantee that marketing surveillance protocols are implemented successfully and consistently. Audits include things like laboratory test documentation, sample collection records, and complaint investigations. CAPA is adopted as a result of audit findings when deviations are discovered.

5.2.1 Training and competency assessment

Quality assurance makes ensuring that employees engaged in marketing surveillance receive sufficient training on SOPs, legal obligations, and quality standards. Periodically, competency evaluations are carried out to ensure high performance and compliance levels.

5.3 QA activities in pharmacovigilance

5.3.1 Case processing quality checks

Individual Case Safety Reports (ICSRs) are examined by QA teams to ensure they are accurate, timely, and comprehensive. This involves confirming that causality evaluations follow established procedures and that all necessary data items are documented.

5.3.2 Pharmacovigilance system audits

System audits assess every step of the pharmacovigilance process, from gathering and entering data to identifying and reporting signals. These audits make sure that regulations, including prompt submission of Periodic Safety Update Reports (PSURs) and Good Pharmacovigilance Practices (GVP), are followed.

5.3.3 Validation of electronic systems

Safety management systems and electronic databases are essential to many pharmacovigilance initiatives. As mandated by laws such as FDA 21 CFR Part 11, QA verifies that these computerized systems function accurately, securely, and preserve data integrity.

5.3.4 Training and continuous improvement

QA is in charge of pharmacovigilance staff training programs on new policies, instruments, and safety issues. On the basis of audit results, regulatory revisions, and technology advancements, it also propels programs for continual improvement.

5.4 Corrective and preventive actions (CAPA)

When audits or investigations reveal non-conformities or deviations, QA oversees CAPA procedures to address the underlying causes and stop them from happening again. Successful CAPA programs lower regulatory risks and strengthen pharmacovigilance and marketing surveillance systems.

5.5 Importance of QA in ensuring data integrity and patient safety

The foundation of trustworthy medication safety monitoring is QA operations. Data inaccuracies, delayed reporting, or non-compliance might weaken safety signals in the absence of strict QA control, delaying regulatory measures and perhaps endangering patients.

6. Integration Of Marketing Surveillance and Pharmacovigilance

6.1 Rationale for integration

Pharmacovigilance and marketing monitoring have historically been handled as distinct tasks, but their combination provides a more thorough method of guaranteeing the quality and safety of drugs. Both fields keep an eye on distinct but related facets of a product's lifecycle: pharmacovigilance is concerned with clinical safety and adverse event monitoring, whereas marketing surveillance is focused on product quality and compliance. By connecting clinical safety results with product quality data, integration makes it easier to identify and address safety or quality concerns early on. Timely regulatory decision-making, efficient risk management, and public health protection all depend on this comprehensive viewpoint.

6.2 Benefits of integration

• Enhanced Signal Detection: By combining pharmacovigilance data with quality defect reports, it is possible to differentiate between adverse events brought on by product degradation and those that are the result of inherent drug toxicity.
• Coordinated Risk Management: Comprehensive risk reduction tactics, like product recalls in line with safety announcements, are supported by joint evaluation.
• Better Regulatory Compliance: Integrated systems guarantee compliance with Good Manufacturing Practices (GMP) and Good Pharmacovigilance Practices (GVP) while streamlining reporting to regulatory bodies.
• Resource Optimization: By sharing information and procedures, operational efficiency is increased and duplication is decreased.

6.3 Practical Implementation Strategies

6.3.1 Data sharing and cross-functional collaboration

Manufacturers and regulatory agencies set up systems for data sharing and communication across manufacturing, pharmacovigilance, regulatory affairs, and quality assurance. In order to make proactive decisions, cross-functional teams examine trends in the combined data.

6.3.2 Unified quality and safety databases

Comprehensive data mining and analysis are made easier by the creation of integrated electronic databases that record adverse event reports as well as quality complaints. These technologies facilitate quick signal recognition and real-time monitoring.

6.3.3 Joint audits and investigations

Thorough evaluation of product problems and their clinical implications is ensured by coordinated audits including quality and safety staff. Analysing patient safety data is part of product complaint investigations.

6.4 Case example: Detection of contaminated drug batches

In 2018, a pharmaceutical company reported an increase in injection site reactions for a widely used intravenous drug. Concurrent marketing surveillance identified a batch with compromised sterility due to packaging defects. The integrated approach prevented further patient harm by enabling targeted safety notifications and prompt product recalls.

6.5 Challenges in integration

• Communication gaps and organizational silos between the safety and quality departments.
• Technical challenges in data system harmonization.
• Complicated regulatory requirements for integrated reporting.

6.6 Future directions

• utilizing artificial intelligence and advanced analytics to combine and examine multifaceted data.
• efforts to standardize integrated reporting formats through global harmonization.
• improved educational initiatives that foster interdisciplinary knowledge.

7. Quality Assurance’s Role in Ensuring Product Safety

Quality assurance, or QA, is crucial to guaranteeing the safety, efficacy, and quality of pharmaceutical products throughout their entire lifecycle. Quality assurance (QA) is the cornerstone of pharmacovigilance and marketing surveillance, ensuring that all practices adhere to stringent industry standards and regulatory requirements, protecting patients from potential harm caused by subpar products or concealed safety issues. Quality assurance (QA) systems are crucial to maintaining the trust of the public, regulators, and healthcare providers because pharmaceutical manufacturing, distribution, and monitoring are complex and global. By encouraging a culture of quality and continuous improvement, QA lowers the risks of adverse drug reactions, product issues, and regulatory non-compliance.

7.1 Establishing robust quality management systems

QA is responsible for developing and maintaining a comprehensive Quality Management System (QMS) that governs marketing surveillance and pharmacovigilance activities. It is necessary to develop, review, and update Standard Operating Procedures (SOPs) that accurately define roles, responsibilities, workflows, and quality standards.
For example, SOPs cover how to handle and document adverse event reports, manage product recalls, and gather samples during market surveillance. Effective staff training is made easier, operational consistency is ensured, and variability is decreased with a well-documented QMS.

7.2 Compliance with regulatory requirements

Good Manufacturing Practices (GMP), Good Distribution Practices (GDP), and Good Pharmacovigilance Practices (GVP) are among the laws that QA ensures are followed by all pharmaceutical operations ¹⁴. In addition to being required by law, this adherence is an essential patient safety measure. Noncompliance may have serious consequences, such as product recalls, fines, and loss of marketing license. For instance, the US FDA mandates that strict adherence to 21 CFR Part 820 for manufacturing quality systems and Part 11 for electronic records used in pharmacovigilance databases. QA audits confirm that these standards are met and maintained¹⁵.

7.3 Audits and inspections

Among QA's main duties are conducting internal audits and supporting regulatory inspections. These audits look closely at marketing surveillance and pharmacovigilance practices to identify gaps, deviations, or non-conformance areas ¹⁶.  For example, insufficient documentation in adverse event case reports or disparities in complaint investigations could be discovered during an audit. QA then begins Corrective and Preventive Actions (CAPA) to address these issues and prevent them from occurring again. Regular audits improve the company's accountability and continuous improvement.

7.4 Ensuring data integrity and documentation control

Dependable and trustworthy data are the foundation of efficient pharmacovigilance and marketing monitoring. QA ensures that data management systems, whether electronic or paper-based, satisfy legal requirements for integrity, security, and traceability. QA oversees the validation of digital systems to ensure compliance with regulations such as FDA 21 CFR Part 11, which governs electronic records and signatures. Documentation control includes safety reports, training records, batch release documents, and SOP version management. Maintaining data integrity enables the detection of safety signals and the timely and accurate submission of regulatory information.

7.5 Training and competency development

QA departments create and carry out training programs for staff members engaged in pharmacovigilance, surveillance, and quality control. It is guaranteed that workers who receive training will comprehend their specific duties, legal obligations, and quality standards. QA frequently sets up competency tests, refresher courses, and policy or technology updates. Employees with the proper training are less likely to make mistakes that could jeopardize legal compliance or product safety.

7.6 Managing corrective and preventive actions (CAPA)

QA performs root cause studies to identify the underlying reasons for deviations, product complaints, or safety signals. CAPA plans are developed to address these issues in two ways: through corrective actions (solving the immediate problem) and preventative strategies (removing the cause to prevent future recurrence).

For example, if a market surveillance batch failure is connected to inadequate storage conditions, CAPA might entail better temperature monitoring and staff retraining on storage protocols. CAPA is necessary to finish the cycle from problem identification to resolution.

7.7 Facilitating continuous improvement

QA encourages continuous quality improvement by analysing audit results, complaint trends, and pharmacovigilance data. Lessons learned inform updates to operating procedures, training programs, and SOPs. Because of this proactive approach, organizations are better equipped to adapt to evolving safety concerns and regulatory environments. As artificial intelligence (AI) for signal detection advances, QA must update data processing and validation protocols to guarantee that new technologies meet quality requirements.

7.8 Collaboration with cross-functional teams

QA acts as a bridge between the marketing, pharmacovigilance, regulatory affairs, and manufacturing teams to ensure that quality and safety operations are seamlessly integrated. When there is good teamwork and communication, product safety is approached holistically. When pharmacovigilance detects an increase in adverse events that might be connected to product quality, for example, QA collaborates with manufacturing to review batch records and distribution data in order to facilitate timely risk mitigation.

8. Real-World Impact of QA on Product Safety

Several historical examples demonstrate the importance of QA in maintaining public health. Modern pharmacovigilance and quality assurance practices were developed globally as a result of the thalidomide tragedy in the 1960s ¹⁷. QA-led investigations have facilitated the prompt recall of contaminated batches in recent years, preventing significant harm.
Organizations with strong QA systems report higher compliance rates, fewer product recalls, and improved patient safety outcomes, all of which emphasize the value of QA.

CONCLUSION

Effective post-marketing drug safety depends on robust quality assurance systems and the collaboration of marketing surveillance and pharmacovigilance. Marketing surveillance ensures product quality, regulatory compliance, and distribution integrity, while pharmacovigilance monitors adverse medication responses, evaluates clinical safety, and maintains a favourable benefit–risk balance throughout a product's lifecycle. Combining these domains improves early detection of safety and quality issues, facilitates coordinated risk management, and strengthens public health protection. The foundation of this integration is quality assurance, which is achieved through the use of standard operating procedures, audits, training, data integrity, and corrective and preventive measures. Even while modern approaches employ global regulatory frameworks, advanced analytics, and interdisciplinary cooperation, past events like the thalidomide tragedy highlight the importance of meticulous post-marketing monitoring. Despite challenges like data silos and regulatory complexity, a proactive, quality-driven, globally harmonized approach ensures that pharmaceuticals continue to be safe, effective, and reliable for patients everywhere.

REFERENCES

1. Younus MM, Al-Jumaili AA. An overview of COVID-19 vaccine safety and post-marketing surveillance systems. INNOVATIONS in Pharmacy. 2021 Oct 12;12(4):8. Available from: https://doi.org/10.24926/iip.v12i4.4294
2. Nishimura JI, Kawaguchi T, Ito S, Murai H, Shimono A, Matsuda T, et al. Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan. International Journal of Hematology. 2023 Jul 29;118(4):419–31. Available from: https://doi.org/10.1007/s12185-023-03630-x
3. Okeke NIC, Agu NEE, Ejike NOG, Ewim NCPM, Komolafe NMO. Developing a regulatory model for product quality assurance in Nigeria’s local industries. International Journal of Frontline Research in Multidisciplinary Studies. 2022 Dec 30;1(2):054–69. Available from: https://doi.org/10.56355/ijfrms.2022.1.2.0055
4. Imran M, Kang C, Ramzan MB. Medicine supply chain model for an integrated healthcare system with uncertain product complaints. Journal of Manufacturing Systems. 2017 Nov 10;46:13–28. Available from: https://doi.org/10.1016/j.jmsy.2017.10.006
5. Ruggiero R, Balzano N, Di Napoli R, Fraenza F, Pentella C, Riccardi C, et al. Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years. Frontiers in Immunology. 2023 Mar 16;14. Available from: https://doi.org/10.3389/fimmu.2023.1134436
6. Zou F, Dong Y, Song S, Rungtusanatham M. Product recalls and supply base innovation. Manufacturing & Service Operations Management. 2023 May 18;25(5):1931–46. Available from: https://doi.org/10.1287/msom.2023.1213
7. Chiappini S, Vickers-Smith R, Harris D, Pelletier GDP, Corkery JM, Guirguis A, et al. Is there a risk for semaglutide misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance dataset. Pharmaceuticals. 2023 Jul 11;16(7):994. Available from: https://doi.org/10.3390/ph16070994
8. Lehrer S, Rheinstein PH, Rosenzweig KE. No relationship of Anti-Androgens to Alzheimer’s disease or cognitive disorder in the MedWatch database. Journal of Alzheimer S Disease Reports. 2018 Mar 6;2(1):123–7. Available from: https://doi.org/10.3233/adr-180052
9. Al-Shamrani A, Alharbi S, Kobeisy S, AlKhater SA, Alalkami H, Alahmadi T, et al. Adverse drug reactions (ADRs) of Montelukast in children. Children. 2022 Nov 21;9(11):1783. Available from: https://doi.org/10.3390/children9111783
10. De Las Cuevas C, Sanz EJ, De Leon J. Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: Comparing the top four reporting countries (US, UK, Canada and Australia). Schizophrenia Research. 2023 Jun 1; Available from: https://doi.org/10.1016/j.schres.2023.05.004
11. Wang H p., Wang C l., Yu W n., Hsu S h., Huang Y w., Lin Y l., et al. From pharmacovigilance to pharmacovigilance planning - The system building for safe medication. Journal of Food and Drug Analysis. 2020 Jul 14;15(4). Available from: https://doi.org/10.38212/2224-6614.2391
12. Toki T, Ono S. Spontaneous reporting on adverse events by consumers in the United States: An analysis of the Food and Drug Administration Adverse Event Reporting System Database. Drugs - Real World Outcomes. 2018 May 3;5(2):117–28. Available from: https://doi.org/10.1007/s40801-018-0134-0
13. Sharma A, Gamta V, Luthra G. The importance of Good Manufacturing Practices (GMP) in the healthcare industry. Journal of Pharmaceutical Research International. 2023 Jul 10;35(18):75–90. Available from: https://doi.org/10.9734/jpri/2023/v35i187394
14. Kumar N, Jha A. Quality risk management during pharmaceutical ‘good distribution practices’ – A plausible solution. Bulletin of Faculty of Pharmacy Cairo University. 2017 Dec 21;56(1):18–25. Available from: https://doi.org/10.1016/j.bfopcu.2017.12.002
15. Kumar S, Srilekha B. Good storage and good distribution practices of pharmaceuticals in India and the USA with regulatory enforcement. International Journal of Clinical Pharmacokinetics and Medical Sciences. 2023 Feb 10;3(1):42–53. Available from: https://doi.org/10.26452/ijcpms.v3i1.495
16. Patil DK, Patil DR, Pati SA. A review on Introduction to Quality assurance. Research Journal of Pharmacology and Pharmacodynamics. 2023 May 20;73–6. Available from: https://doi.org/10.52711/2321-5836.2023.00015
17. Aggarwal R, Nautiyal A, Joshi Y. Thalidomide - the disastrous drug. Asian Journal of Research in Pharmaceutical Sciences. 2023 Aug 26;241–7. Available from: https://doi.org/10.52711/2231-5659.2023.00042.